Share Name Share Symbol Market Type Share ISIN Share Description
Indivior LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.80p -1.58% 298.10p 297.90p 298.10p 301.70p 296.40p 299.80p 1,323,547.00 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 688.2 193.4 21.7 11.5 2,171.89

Indivior Share Discussion Threads

Showing 176 to 197 of 200 messages
Chat Pages: 8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
09/1/2017
14:59
Yes,it reads well.
steeplejack
09/1/2017
13:39
Just read the various PDF slides to be used accompanying the JP Morgan Conference to be held in 2 days time. Bit strange its published two days beforehand but I am not complaining! All stills seems up quite upbeat. Answers on the litigation not discernible to me but I guess some progress being made. Market seems to like it. Re the stated revenue upgraded projection, I am not sure whether this is just a restatement from the last quarterly statement or not-- but am assuming so.
gregmorg
17/12/2016
15:18
Jeffries was the upgrade on 16 Dec....target price now 440p,BUY
steeplejack
16/12/2016
09:37
Not sure who has updated today but here's a list of latest forecasts.Yesterday was a tree shake then.Could make one rather cynical.Closing price Old price target New price target Broker change12-Dec-16 Deutsche Buy 289.60p - 395.00p Reiteration15-Nov-16 Deutsche Buy 346.90p - 400.00p Reiteration07-Nov-16 Jefferies Buy 352.40p 370.00p 450.00p Reiteration03-Nov-16 Deutsche Buy 369.00p 395.00p 400.00p Reiteration03-Nov-16 numis Buy 369.00p - 450.00p Reiteration26-Oct-16 numis Buy 314.50p - 370.00p Reiteration22-Aug-16 Jefferies Buy 320.30p 330.00p 370.00p Reiteration17-Aug-16 numis Buy 327.40p - 370.00p Reiteration09-Aug-16 RBC Capital Markets Sector perform 298.30p 185.00p 325.00p Reiteration26-Jul-16 Jefferies Buy 272.20p 285.00p 320.00p Reiteration19-Jul-16 Citigroup Neutral 268.90p - 280.00p DownGrade29-Jun-16 Jefferies Buy 239.50p
steeplejack
16/12/2016
08:22
lovely upgrade today buy PT 4.80
bigboots
15/12/2016
09:31
Litigation news?
steeplejack
15/12/2016
09:28
Bit of volume coming thru, is there news out there, cant see anything on the wires...
bigboots
15/12/2016
09:21
Someone thinks they have a story but since the stock is now well over a pound or some 30% off the years high,I guess I can only conclude I've missed the boat.Things are pretty feral at the moment and pre Trump,it appears easy to knock the stuffing out of a stock with little more than a Twitter.A perversely brave new world dominated by computer trading and spurious rumour.
steeplejack
14/12/2016
12:48
Will bear with it, as always, but the current malaise is becoming tedious. Mind you that's the current experience with similar stocks. They appear to react positively to good news but not much else and not for long!
gregmorg
08/12/2016
08:40
I think the CMA decision to fine Pfizer over the pricing of its anti epilepsy drug had a wash through effect here.Natter about unfair pricing,compromising generic competition etc,all potentially very relevant re anti trust allegations surrounding Suboxone.Time will tell.There's a witch hunt going on.
steeplejack
07/12/2016
18:06
Could well be right! I note the property market has escaped the Trump affect so far. Could I assume that he will pronounce adversely on that at some stage!!
gregmorg
07/12/2016
17:35
From aircraft to refrigeration and drug manufacturers,Mr Trump has a view on all things.I think with litigation in the wings,the price fall today was reactive rather than predictive but that's a guess of course.The drug stocks have lost their mojo in a market that fairly slavishly follows bonds in feeling that US growth and inflation are on the horizon.Many slip between cup and lip.
steeplejack
07/12/2016
17:24
Mm, Volume surprisingly high here. The R and D day is on the 9th December and starts at 7.30 am NY time . Obviously someone somewhere either knows or wants us to believe they know something. We are awaiting a further legal ruling on the various patent cases but this is actually a tad behind the envisaged schedule. Maybe Mr Trump has panicked a holder but I will sit and wait for news. Over the years in many/most stocks its worked for me.
gregmorg
07/12/2016
16:37
Trump's twitters have weakened sentiment towards drug stocks with talk of imposing drug price cuts.He's going to be a busy little bee when he takes office.He makes for a feral equity market with his unencrypted comments.
steeplejack
09/11/2016
08:52
And up go all the drug stocks on the Trump victory.Back in the 1990s ,I went to a Smithkline Beecham meeting.At the front of the hall was a photo of Hilary Clinton."You're probably wondering why we have this photograph here", said a member of the SKB team,"it's here to remind you that this woman is NOT the President of the United States!"The dislike of Hilary Clinton is pretty universal amongst drug companies emanating from all those years ago when she attacked their practises and profitability.Today we're enjoying a relief rally that she's not in power.
steeplejack
07/11/2016
10:39
remembr though that the litigation problem remains - i wont add until this is resolved
ali47fish
07/11/2016
09:49
Thanks for the link. It provides a great read.
gregmorg
04/11/2016
11:09
Steeplejack, only you and I seem to post on this one! I listened to the conference call on the trading update and one question interested me. An analyst referred to the $220m legal provision and queried whether Reckitt had any potential liability. Indivior stonewalled as it did on all legal provision questions but the CEO acknowledged, but only when pointed out, that Reckitt had made a reference to the legal situation in its last trading update(19 October although I missed it). I have pasted the extract below. Reckitt appears to be acknowledging that it could have some liability. Obviously some warrenties would have been given at the time of the demerger, as they always are in these situations. Maybe that statement spurred Indivior on to making a provision now! "Indivior / RB Pharma related matters: We noted in our 2015 Annual Report and 2016 interim announcement that the Group was involved in ongoing investigations by the US Department of Justice and the US Federal Trade Commission and related litigation proceedings in relation to certain matters relating to the RB Pharmaceuticals business prior to its demerger in December 2014 to form Indivior PLC and may incur liabilities in relation to such matters. These investigations and related proceedings are continuing and the outcome for the Group at this stage remains uncertain. The Company continues to work to ensure that these investigations and related proceedings are concluded or resolved satisfactorily."
gregmorg
02/11/2016
12:51
Mm, so the market likes the 3rd qtr. The upgraded revenue forecasts for the year are encouraging as is the gradual development of the product pipeline. Could be great excitement down the line from these new products! Yet the litigation situation is to me so complex I just cannot get my head around it. It might be the $220m provision is the first quantification of downside possibilities and investors are reassured but at this stage that scenario seems too simplistic. No doubt will learn more in time.
gregmorg
24/9/2016
22:44
Article seems to suggest the generic plaintiffs believe INDV shouldn't have tried to find alternative delivery methods, which can be patent protected and where there are no generics. Hardly the attitude of the land of the free. However I am concerned about the effect of the suit in the medium term, considering the behaviour of Illumina against NIPT and the effect on its share price
bscuit
24/9/2016
11:52
Looking at the situation and without huge knowledge, the 35 States appear to be attempting to turn a corporate competive advantage into something else. Can see why the Company is vigorously defending its position.
gregmorg
23/9/2016
11:56
From Interim statement In August 2015, the Company was informed that a contingent of additional states has initiated a coordinated investigation into the same conduct that is the subject of the FTC investigation and the Class Action litigation. The existing investigation of these same issues by the State of New York has now been incorporated within this multi-state investigation. On July 1, 2016, Indivior Inc. was notified that 22 states and the District of Columbia intend to file a complaint in the Eastern District of Pennsylvania alleging violations of state and federal antitrust and consumer protection laws relating to the same conduct. The notice indicated that additional states may decide to join in any action and more recently the Company has learned that additional states do intend to join. -- Fact discovery is underway in the Class Action litigation. -- Amneal Pharmaceuticals LLC, a manufacturer of generic buprenorphine / naloxone tablets, has joined the litigation as an additional plaintiff. Amneal's complaint contains antitrust allegations similar in nature to those set out in the class action complaints, and Amneal has also alleged violations of the Lanham Act.Department of Justice Investigation
steeplejack
Chat Pages: 8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170121 02:14:23